Bioengineering professors Kevin Healy and Luke Lee and collaborators are one of only eleven top university teams nationwide to receive a Phase Two Tissue Chip Award from the NIH National Center for Advancing Translational Sciences (NCATS).
The Tissue Chip for Drug Screening initiative was designed to improve ways of predicting drug safety and effectiveness, with Phase Two encouraging scientists to collaborate to combine tissue chips into an integrated system that can mimic the complex functions of the human body. The two-year award will support Healy and Lee in their efforts to integrate human heart and liver tissues into a functional, 3-D model to screen candidate drugs for toxic side effects.
Congratulations!
Read more about the 2014 Tissue Chip Awards.